EKF Diagnostics Holdings plc
("EKF" or the "Company")
Purchase of own shares and PDMR Dealing
EKF Diagnostics Holdings plc (AIM: EKF), the AIM listed medical diagnostics business, announces an update to its prior announcement on 14 November 2018 in relation to the Buy-Back. The Company confirms that on 20 November 2018, it purchased 1,641,493 of its ordinary shares on the London Stock Exchange at a price of 27.4348 pence per share. The purchased shares will be cancelled.
Aggregated information:
|
Date of purchase: |
20 November 2018 |
|
Issuer name: |
EKF Diagnostics Holdings plc |
|
ISIN: |
GB0031509804 |
|
Number of ordinary shares purchased: |
1,641,493 |
|
Volume weighted average price paid per share: |
27.4348 pence |
|
Trading venue |
London Stock Exchange |
Transaction details:
In accordance with Article 5(1)(b) of Regulation (EU) No 596/2014 (the Market Abuse Regulation), a full breakdown of the individual trades made by N+1 Singer on behalf of the Company as part of the Buy-Back programme is detailed below:
|
Number of shares purchased |
Transaction price (GBp) |
Time of transaction |
Trading venue |
|
1,000,000 |
27.50 |
12:50:25 |
AIMX |
|
427,385 |
27.50 |
13:06:46 |
AIMX |
|
150,000 |
27.00 |
15:48:04 |
AIMX |
|
64,108 |
27.00 |
16:02:27 |
AIMX |
Total Voting Rights
Following the cancellation, the Company's total issued share capital will consist of 455,734,720 shares of 1 pence each ("Ordinary Shares") with one voting right per share. The Company will not hold any Ordinary Shares in treasury. Therefore, the total number of voting rights in the Company will be 455,734,720.
The above figure of 455,734,720 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure and Transparency Rules.
PDMR dealing
As part of the Buy-Back and within the above aggregate purchase, EKF acquired 491,493 ordinary shares at a price 27.4348 pence per share from Harwood Capital LLP ("Harwood") as investment manager to Oryx International Growth Fund Limited ("Oryx"). Christopher Mills, the Company's Non-Executive Chairman, is a partner and Chief Investment Officer of Harwood and a director and shareholder in Oryx. As stated in the announcement of 14 November, Harwood has facilitated this transaction solely in order to ensure that the aggregate indirect beneficial interest of Mr. Mills remains at approximately the same level and in any event does not exceed 30% of the prevailing total voting rights in the Company following any repurchases.
Following the above sale of ordinary shares by Oryx to the Company, Mr. Mills' aggregate indirect interest in the Company is 136,455,084 ordinary shares, representing 29.94 per cent. of the total voting rights in EKF. 38,455,084 of these shares are held by Oryx and the balance by North Atlantic Smaller Companies Investment Trust PLC ("NASCIT"), an investment trust to which Harwood acts as an investment adviser and of which Christopher Mills is a director and shareholder.
Additional disclosures relating to this PDMR dealing are detailed below.
For further information please contact:
|
EKF Diagnostics Holdings plc |
Tel: 029 2071 0570 |
|
Christopher Mills, Non-Executive Chairman |
|
|
Julian Baines, CEO |
|
|
Richard Evans, FD & COO |
|
|
|
|
|
N+1 Singer (Nominated Adviser & Broker) |
Tel: 020 7496 3000 |
|
Aubrey Powell / Lauren Kettle / George Tzimas (Corporate Finance) |
|
|
Tom Salvesen / Ross Penney (Corporate Broking) |
|
|
Walbrook PR Limited |
Tel: 020 7933 8780 or ekf@walbrookpr.com |
|
Paul McManus / Lianne Cawthorne |
Mobile: 07980 541 893 / 07584 391 303 |
About EKF Diagnostics Holdings plc www.ekfdiagnostics.com
EKF is a leading point-of-care diagnostics and central laboratory assay manufacturer with an estimated 80,000 hemoglobin, hematocrit, HbA1c, glucose and lactate analyzers in regular use across more than 100 countries. EKF specializes in developing tests for use in anemia and diabetes diagnosis and management, as well as providing a portfolio of reagents for use in clinical chemistry analyzers.
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
|
1
|
Details of the person discharging managerial responsibilities / person closely associated
|
||||
|
a)
|
Name
|
Harwood Capital LLP, as investment manager to Oryx International Growth Fund Limited ("Oryx") |
|||
|
2
|
Reason for the notification
|
||||
|
a)
|
Position/status
|
Christopher Mills, the Company's Non-Executive Chairman, is a partner and Chief Investment Officer of Harwood Capital LLP and a director and shareholder in Oryx |
|||
|
b)
|
Initial notification /Amendment
|
Initial notification |
|||
|
3
|
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
|
||||
|
a)
|
Name
|
EKF Diagnostics Holdings plc |
|||
|
b)
|
LEI
|
213800DXTF3EAUK1AR05 |
|||
|
4
|
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
|
||||
|
a)
|
Description of the financial instrument, type of instrument |
Ordinary shares of 1 pence each |
|||
|
|
|
||||
|
Identification code |
ISIN Code: GB0031509804 |
||||
|
|
|
||||
|
b)
|
Nature of the transaction
|
Sale of shares |
|||
|
c)
|
Price(s) and volume(s) |
|
|
|
|
|
|
|
Price(s) |
Volume(s) |
|
|
|
|
|
27.4348 pence |
491,493 |
|
|
|
|
|
|
|
|
|
|
d)
|
Aggregated information |
n/a |
|||
|
|
|
||||
|
- Aggregated volume |
|
||||
|
|
|
||||
|
- Price |
|
||||
|
|
|
||||
|
e)
|
Date of the transaction
|
20 November 2018 |
|||
|
f)
|
Place of the transaction |
London Stock Exchange |
|||